| Ytd | -31.94% | |
| 1y | -62.16% |
| Open | 1.92 | Prev Close | 1.92 | Low | 1.84 | High | 1.96 | Mkt Cap | 5.48M |
| Vol | 6.41K | Avg Vol | 238.80K | EPS | 0.65 | P/E | 3.02 | Forward P/E | -0.39 |
| Beta | 0.60 | Short Ratio | 2.45 | Inst. Own | 1.49% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 2.22 | 200-d Avg | 2.81 | 1yr Est | 6.00 |
PCSA News
VERO BEACH, FL, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a
Processa Pharmaceuticals, Inc. (PCSA) M&A Call Prepared Remarks Transcript
Gainers Autonomix Medical (NASDAQ:AMIX) shares increased by 89.4% to $5.21 during Wednesday's r
Dow Jones falls 800+ pts; energy shares up 2.6%; General Dynamics beats earnings estimates; Verra Mo
US stocks mostly lower, Dow Jones falls 400+ pts. Energy shares up 3%. Procter & Gamble shares d
Processa Pharmaceuticals said on Wednesday it acquired privately held Vidya Therapeutics in an all-s
Gainers Autonomix Medical (NASDAQ:AMIX) shares moved upwards by 62.5% to $4.47 during Wednesday'
Acquisition brings into Processa's pipeline Vidya's lead asset, VT-7208, a next-generation, CNS-pene
Gainers Advanced Biomed (NASDAQ:ADVB) shares moved upwards by 108.6% to $14.77 during Wednesday'
Heatwurx (NASDAQ: PCSA - Get Free Report) and Stevanato Group (NYSE: STVN - Get Free Report) are bot
Heatwurx (NASDAQ: PCSA - Get Free Report) and Aquestive Therapeutics (NASDAQ: AQST - Get Free Report
VERO BEACH, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a
Interim safety and efficacy data to be reported in Q1VERO BEACH, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE
Interim safety and efficacy data to be reported in Q1 VERO BEACH, Fla., Jan. 05, 2026 (GLOBE NEWSWIR
Processa Pharmaceuticals stock jumps 122% after a phase II update shows NGC-Cap delivers higher acti
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) stock is skyrocketing on Wednesday, with a session vol
Processa Pharmaceuticals' stock jumps after Phase 2 data show higher capecitabine exposure witho
Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposu
Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposu
On December 12, 2025, Processa Pharmaceuticals, Inc. (the "Company") filed with the Secretar
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical-stage biopharmaceutical company developing
VERO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a
Processa Pharmaceuticals shares jumped 37.5% after hours following a strong regular session, despite
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Processa Pharmaceuticals (NASDAQ:PCS
Processa Pharma (NASDAQ:PCSA) reported quarterly losses of $(0.25) per share which missed the analys
VERO BEACH, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a
Signed binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852Contin
Signed binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852 Conti
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Processa Pharmaceuticals (NASDAQ:PCS